REFERENCES
1. Teede HJ, Tay CT, Laven JJE, et al. Recommendations from the 2023 International Evidence-based Guideline for the assessment and management of polycystic ovary syndrome. J Clin Endocrinol Metab. 2023;108:2447-69.
3. ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19:41-7.
4. Sivanandy MS, Ha SK. The role of serum anti-mullerian hormone measurement in the diagnosis of polycystic ovary syndrome. Diagnostics. 2023;13:907.
5. Stener-Victorin E, Padmanabhan V, Walters KA, et al. Animal models to understand the etiology and pathophysiology of polycystic ovary syndrome. Endocr Rev. 2020;41:bnaa010.
6. Hart R, Hickey M, Franks S. Definitions, prevalence and symptoms of polycystic ovaries and polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol. 2004;18:671-83.
7. Deeks AA, Gibson-Helm ME, Teede HJ. Anxiety and depression in polycystic ovary syndrome: a comprehensive investigation. Fertil Steril. 2010;93:2421-3.
8. Dunaif A, Segal KR, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes. 1989;38:1165-74.
9. Carmina E, Lobo RA. Use of fasting blood to assess the prevalence of insulin resistance in women with polycystic ovary syndrome. Fertil Steril. 2004;82:661-5.
10. Lemaitre M, Christin-Maitre S, Kerlan V. Polycystic ovary syndrome and adipose tissue. Ann Endocrinol. 2023;84:308-15.
11. Spritzer PM, Lecke SB, Satler F, Morsch DM. Adipose tissue dysfunction, adipokines, and low-grade chronic inflammation in polycystic ovary syndrome. Reproduction. 2015;149:R219-27.
12. Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature. 2006;444:840-6.
13. Kakoly NS, Earnest A, Teede HJ, Moran LJ, Joham AE. The impact of obesity on the incidence of type 2 diabetes among women with polycystic ovary syndrome. Diabetes Care. 2019;42:560-7.
14. Chantrapanichkul P, Indhavivadhana S, Wongwananuruk T, Techatraisak K, Dangrat C, Sa-Nga-Areekul N. Prevalence of type 2 diabetes mellitus compared between lean and overweight/obese patients with polycystic ovarian syndrome: a 5-year follow-up study. Arch Gynecol Obstet. 2020;301:809-16.
15. Samaras K, Botelho NK, De Glizesinski J, Lord RV. Subcutaneous and visceral adipose tissue gene expression of serum adipokines that predict type 2 diabetes. Obesity. 2010;18:884-9.
16. De Glisezinski I, Larrouy D, Bajzova M, et al. Adrenaline but not noradrenaline is a determinant of exercise-induced lipid mobilization in human subcutaneous adipose tissue. J Physiol. 2009;587:3393-404.
17. Shoupe D, Kumar DD, Lobo RA. Insulin resistance in polycystic ovary syndrome. Am J Obstet Gynecol. 1983;147:588-92.
18. Chang RJ, Nakamura RM, Judd HL, Kaplan SA. Insulin resistance in nonobese patients with polycystic ovarian disease. J Clin Endocrinol Metab. 1983;57:356-9.
19. Baillargeon JP, Carpentier A. Role of insulin in the hyperandrogenemia of lean women with polycystic ovary syndrome and normal insulin sensitivity. Fertil Steril. 2007;88:886-93.
20. Dumesic DA, Abbott DH. Implications of polycystic ovary syndrome on oocyte development. Semin Reprod Med. 2008;26:53-61.
21. Hong SH, Sung YA, Hong YS, Jeong K, Chung H, Lee H. Polycystic ovary morphology is associated with insulin resistance in women with polycystic ovary syndrome. Clin Endocrinol. 2017;87:375-80.
22. Diamanti-Kandarakis E, Xyrafis X, Boutzios G, Christakou C. Pancreatic beta-cells dysfunction in polycystic ovary syndrome. Panminerva Med. 2008;50:315-25.
23. Dunaif A, Finegood DT. Beta-cell dysfunction independent of obesity and glucose intolerance in the polycystic ovary syndrome. J Clin Endocrinol Metab. 1996;81:942-7.
24. Mishra JS, More AS, Kumar S. Elevated androgen levels induce hyperinsulinemia through increase in Ins1 transcription in pancreatic beta cells in female rats. Biol Reprod. 2018;98:520-31.
25. Wang H, Wang X, Zhu Y, Chen F, Sun Y, Han X. Increased androgen levels in rats impair glucose-stimulated insulin secretion through disruption of pancreatic beta cell mitochondrial function. J Steroid Biochem Mol Biol. 2015;154:254-66.
26. Malin SK, Kirwan JP, Sia CL, González F. Glucose-stimulated oxidative stress in mononuclear cells is related to pancreatic β-cell dysfunction in polycystic ovary syndrome. J Clin Endocrinol Metab. 2014;99:322-9.
27. Rae M, Grace C, Hogg K, et al. The pancreas is altered by in utero androgen exposure: implications for clinical conditions such as polycystic ovary syndrome (PCOS). PLoS One. 2013;8:e56263.
28. Vine D, Ghosh M, Wang T, Bakal J. Increased prevalence of adverse health outcomes across the lifespan in those affected by polycystic ovary syndrome: a canadian population cohort. CJC Open. 2024;6:314-26.
29. Liao WT, Huang JY, Lee MT, Yang YC, Wu CC. Higher risk of type 2 diabetes in young women with polycystic ovary syndrome: a 10-year retrospective cohort study. World J Diabetes. 2022;13:240-50.
30. Azziz R. Polycystic ovary syndrome, insulin resistance, and molecular defects of insulin signaling. J Clin Endocrinol Metab. 2002;87:4085-7.
31. World Health Organization. Diabetes. Available from https://www.who.int/health-topics/diabetes [accessed 7 March 2025].
32. Chawla A, Chawla R, Jaggi S. Microvasular and macrovascular complications in diabetes mellitus: distinct or continuum? Indian J Endocrinol Metab. 2016;20:546-51.
33. International Diabetes Federation. IDF Diabetes Atlas 2021. Available from https://diabetesatlas.org/atlas/tenth-edition/ [accessed 7 March 2025].
34. Tinajero MG, Malik VS. An update on the epidemiology of type 2 diabetes: a global perspective. Endocrinol Metab Clin North Am. 2021;50:337-55.
35. Bellou V, Belbasis L, Tzoulaki I, Evangelou E. Risk factors for type 2 diabetes mellitus: an exposure-wide umbrella review of meta-analyses. PLoS One. 2018;13:e0194127.
36. Ryu KJ, Kim MS, Kim HK, et al. Risk of type 2 diabetes is increased in nonobese women with polycystic ovary syndrome: the National Health Insurance Service-National Sample Cohort Study. Fertil Steril. 2021;115:1569-75.
37. Livadas S, Paparodis R, Anagnostis P, et al. Assessment of type 2 diabetes risk in young women with polycystic ovary syndrome. Diagnostics. 2023;13:2067.
38. Holte J, Gennarelli G, Wide L, Lithell H, Berne C. High prevalence of polycystic ovaries and associated clinical, endocrine, and metabolic features in women with previous gestational diabetes mellitus. J Clin Endocrinol Metab. 1998;83:1143-50.
39. Kousta E, Cela E, Lawrence N, et al. The prevalence of polycystic ovaries in women with a history of gestational diabetes. Clin Endocrinol. 2000;53:501-7.
40. Conn JJ, Jacobs HS, Conway GS. The prevalence of polycystic ovaries in women with type 2 diabetes mellitus. Clin Endocrinol. 2000;52:81-6.
41. Long C, Feng H, Duan W, et al. Prevalence of polycystic ovary syndrome in patients with type 2 diabetes: a systematic review and meta-analysis. Front Endocrinol. 2022;13:980405.
42. Baillargeon JP, Nestler JE. Commentary: polycystic ovary syndrome: a syndrome of ovarian hypersensitivity to insulin? J Clin Endocrinol Metab. 2006;91:22-4.
43. Risal S, Pei Y, Lu H, et al. Prenatal androgen exposure and transgenerational susceptibility to polycystic ovary syndrome. Nat Med. 2019;25:1894-904.
44. Zhang J, Zhang FJ, Zhang L, et al. Identification of key genes and molecular pathways in type 2 diabetes mellitus and polycystic ovary syndrome via bioinformatics analyses. Eur Rev Med Pharmacol Sci. 2023;27:3255-69.
45. Shaaban Z, Khoradmehr A, Amiri-Yekta A, Nowzari F, Jafarzadeh Shirazi MR, Tamadon A. Pathophysiologic mechanisms of insulin secretion and signaling-related genes in etiology of polycystic ovary syndrome. Genet Res. 2021;2021:7781823.
46. Abbott DH, Dumesic DA, Franks S. Developmental origin of polycystic ovary syndrome - a hypothesis. J Endocrinol. 2002;174:1-5.
47. Tata B, Mimouni NEH, Barbotin AL, et al. Elevated prenatal anti-Müllerian hormone reprograms the fetus and induces polycystic ovary syndrome in adulthood. Nat Med. 2018;24:834-46.
48. Shen HR, Qiu LH, Zhang ZQ, Qin YY, Cao C, Di W. Genome-wide methylated DNA immunoprecipitation analysis of patients with polycystic ovary syndrome. PLoS One. 2013;8:e64801.
49. Makrinou E, Drong AW, Christopoulos G, et al. Genome-wide methylation profiling in granulosa lutein cells of women with polycystic ovary syndrome (PCOS). Mol Cell Endocrinol. 2020;500:110611.
50. Mimouni NEH, Paiva I, Barbotin AL, et al. Polycystic ovary syndrome is transmitted via a transgenerational epigenetic process. Cell Metab. 2021;33:513-30.e8.
51. Parker J. Pathophysiological effects of contemporary lifestyle on evolutionary-conserved survival mechanisms in polycystic ovary syndrome. Life. 2023;13:1056.
52. Bruni V, Capozzi A, Lello S. The role of genetics, epigenetics and lifestyle in polycystic ovary syndrome development: the state of the art. Reprod Sci. 2022;29:668-79.
54. Azarova I, Polonikov A, Klyosova E. Molecular genetics of abnormal redox homeostasis in type 2 diabetes mellitus. Int J Mol Sci. 2023;24:4738.
55. Grant SF, Thorleifsson G, Reynisdottir I, et al. Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet. 2006;38:320-3.
56. Zhou Y, Park SY, Su J, et al. TCF7L2 is a master regulator of insulin production and processing. Hum Mol Genet. 2014;23:6419-31.
57. Ding W, Xu L, Zhang L, et al. Meta-analysis of association between TCF7L2 polymorphism rs7903146 and type 2 diabetes mellitus. BMC Med Genet. 2018;19:38.
58. Sakers A, De Siqueira MK, Seale P, Villanueva CJ. Adipose-tissue plasticity in health and disease. Cell. 2022;185:419-46.
59. Azevedo-Martins AK, Santos MP, Abayomi J, Ferreira NJR, Evangelista FS. The impact of excessive fructose intake on adipose tissue and the development of childhood obesity. Nutrients. 2024;16:939.
60. Scheja L, Heeren J. The endocrine function of adipose tissues in health and cardiometabolic disease. Nat Rev Endocrinol. 2019;15:507-24.
61. Basolo A, Bechi Genzano S, Piaggi P, Krakoff J, Santini F. Energy balance and control of body weight: possible effects of meal timing and circadian rhythm dysregulation. Nutrients. 2021;13:1-13.
62. Horwitz A, Birk R. Adipose tissue hyperplasia and hypertrophy in common and syndromic obesity-the case of BBS obesity. Nutrients. 2023;15:3445.
63. Li Q, Spalding KL. The regulation of adipocyte growth in white adipose tissue. Front Cell Dev Biol. 2022;10:1003219.
64. Loos RJF, Yeo GSH. The genetics of obesity: from discovery to biology. Nat Rev Genet. 2022;23:120-33.
65. Kurokawa N, Young EH, Oka Y, et al. The ADRB3 Trp64Arg variant and BMI: a meta-analysis of 44 833 individuals. Int J Obes. 2008;32:1240-9.
66. Wang D, Ma J, Zhang S, et al. Association of the MC4R V103I polymorphism with obesity: a Chinese case-control study and meta-analysis in 55,195 individuals. Obesity. 2010;18:573-9.
67. Ponce-Gonzalez JG, Martínez-Ávila Á, Velázquez-Díaz D, et al. Impact of the FTO gene variation on appetite and fat oxidation in young adults. Nutrients. 2023;15:2037.
68. Sun K, Kusminski CM, Scherer PE. Adipose tissue remodeling and obesity. J Clin Invest. 2011;121:2094-101.
69. Targher G, Corey KE, Byrne CD, Roden M. The complex link between NAFLD and type 2 diabetes mellitus - mechanisms and treatments. Nat Rev Gastroenterol Hepatol. 2021;18:599-612.
70. Oh YS, Bae GD, Baek DJ, Park EY, Jun HS. Fatty acid-induced lipotoxicity in pancreatic beta-cells during development of type 2 diabetes. Front Endocrinol. 2018;9:384.
71. Azevedo-Martins AK, Monteiro AP, Lima CL, Lenzen S, Curi R. Fatty acid-induced toxicity and neutral lipid accumulation in insulin-producing RINm5F cells. Toxicol In Vitro. 2006;20:1106-13.
72. Shi J, Fan J, Su Q, Yang Z. Cytokines and abnormal glucose and lipid metabolism. Front Endocrinol. 2019;10:703.
73. Zorena K, Jachimowicz-Duda O, Ślęzak D, Robakowska M, Mrugacz M. Adipokines and obesity. Potential link to metabolic disorders and chronic complications. Int J Mol Sci. 2020;21:3570.
74. Marroquí L, Gonzalez A, Nẽco P, et al. Role of leptin in the pancreatic β-cell: effects and signaling pathways. J Mol Endocrinol. 2012;49:R9-17.
75. Nieto-Vazquez I, Fernández-Veledo S, Krämer DK, Vila-Bedmar R, Garcia-Guerra L, Lorenzo M. Insulin resistance associated to obesity: the link TNF-alpha. Arch Physiol Biochem. 2008;114:183-94.
76. Stephens LA, Thomas HE, Ming L, et al. Tumor necrosis factor-α-activated cell death pathways in NIT-1 insulinoma cells and primary pancreatic β cells. Endocrinology. 1999;140:3219-27.
77. Ammendrup A, Maillard A, Nielsen K, et al. The c-Jun amino-terminal kinase pathway is preferentially activated by interleukin-1 and controls apoptosis in differentiating pancreatic beta-cells. Diabetes. 2000;49:1468-76.
78. Diabetes Association Professional Practice Committee. 2. Diagnosis and classification of diabetes: standards of care in diabetes-2024. Diabetes Care. 2024;47:S20-42.
79. Echiburú B, Pérez-Bravo F, Galgani JE, et al. Enlarged adipocytes in subcutaneous adipose tissue associated to hyperandrogenism and visceral adipose tissue volume in women with polycystic ovary syndrome. Steroids. 2018;130:15-21.
80. Chen L, Xu WM, Zhang D. Association of abdominal obesity, insulin resistance, and oxidative stress in adipose tissue in women with polycystic ovary syndrome. Fertil Steril. 2014;102:1167-74.e4.
81. Xiong T, Rodriguez Paris V, Edwards MC, et al. Androgen signaling in adipose tissue, but less likely skeletal muscle, mediates development of metabolic traits in a PCOS mouse model. Am J Physiol Endocrinol Metab. 2022;323:E145-58.
82. Scarfò G, Daniele S, Fusi J, et al. Metabolic and molecular mechanisms of diet and physical exercise in the management of polycystic ovarian syndrome. Biomedicines. 2022;10:1305.
83. Panidis D, Tziomalos K, Papadakis E, Vosnakis C, Chatzis P, Katsikis I. Lifestyle intervention and anti-obesity therapies in the polycystic ovary syndrome: impact on metabolism and fertility. Endocrine. 2013;44:583-90.
84. Almenning I, Rieber-Mohn A, Lundgren KM, Shetelig Løvvik T, Garnæs KK, Moholdt T. Effects of high intensity interval training and strength training on metabolic, cardiovascular and hormonal outcomes in women with polycystic ovary syndrome: a pilot study. PLoS One. 2015;10:e0138793.
85. Leidy HJ, Clifton PM, Astrup A, et al. The role of protein in weight loss and maintenance. Am J Clin Nutr. 2015;101:1320S-9S.
86. Kogure GS, Miranda-Furtado CL, Silva RC, et al. Resistance exercise impacts lean muscle mass in women with polycystic ovary syndrome. Med Sci Sports Exerc. 2016;48:589-98.
87. Kite C, Lahart IM, Afzal I, et al. Exercise, or exercise and diet for the management of polycystic ovary syndrome: a systematic review and meta-analysis. Syst Rev. 2019;8:51.
88. Ribeiro VB, Kogure GS, Lopes IP, et al. Effects of continuous and intermittent aerobic physical training on hormonal and metabolic profile, and body composition in women with polycystic ovary syndrome: a randomized controlled trial. Clin Endocrinol. 2020;93:173-86.
89. Patten RK, Boyle RA, Moholdt T, et al. Exercise interventions in polycystic ovary syndrome: a systematic review and meta-analysis. Front Physiol. 2020;11:606.
90. Breyley-Smith A, Mousa A, Teede HJ, Johnson NA, Sabag A. The effect of exercise on cardiometabolic risk factors in women with polycystic ovary syndrome: a systematic review and meta-analysis. Int J Environ Res Public Health. 2022;19:1386.
91. Mohammadi S, Monazzami A, Alavimilani S. Effects of eight-week high-intensity interval training on some metabolic, hormonal and cardiovascular indices in women with PCOS: a randomized controlled trail. BMC Sports Sci Med Rehabil. 2023;15:47.
92. Ruiz-González D, Cavero-Redondo I, Hernández-Martínez A, et al. Comparative efficacy of exercise, diet and/or pharmacological interventions on BMI, ovulation, and hormonal profile in reproductive-aged women with overweight or obesity: a systematic review and network meta-analysis. Hum Reprod Update. 2024;30:472-87.
93. Gómez-Ambrosi J, Silva C, Galofré JC, et al. Body adiposity and type 2 diabetes: increased risk with a high body fat percentage even having a normal BMI. Obesity. 2011;19:1439-44.
94. Orio F, Muscogiuri G, Giallauria F, et al. Oral contraceptives versus physical exercise on cardiovascular and metabolic risk factors in women with polycystic ovary syndrome: a randomized controlled trial. Clin Endocrinol. 2016;85:764-71.
95. Aktaş HŞ, Uzun YE, Kutlu O, et al. The effects of high intensity-interval training on vaspin, adiponectin and leptin levels in women with polycystic ovary syndrome. Arch Physiol Biochem. 2022;128:37-42.
96. Vizza L, Smith CA, Swaraj S, Agho K, Cheema BS. The feasibility of progressive resistance training in women with polycystic ovary syndrome: a pilot randomized controlled trial. BMC Sports Sci Med Rehabil. 2016;8:14.
97. Miranda-Furtado CL, Ramos FK, Kogure GS, et al. A nonrandomized trial of progressive resistance training intervention in women with polycystic ovary syndrome and its implications in telomere content. Reprod Sci. 2016;23:644-54.
98. Saremi A, Yaghoubi MS. Effect of resistance exercises with calcium consumption on level of anti-mullerian hormone and some metabolic indices in women with polycystic ovarian syndrome. Iran J Obstet Gynecol Infertil. 2016;18:7-15.
99. Kite C, Parkes E, Taylor SR, et al. Time to load up-resistance training can improve the health of women with polycystic ovary syndrome (PCOS): a scoping review. Med Sci. 2022;10:53.
100. Chou TJ, Lin LY, Lu CW, Hsu YJ, Huang CC, Huang KC. Effects of aerobic, resistance, and high-intensity interval training on thermogenic gene expression in white adipose tissue in high fat diet induced obese mice. Obes Res Clin Pract. 2024;18:64-72.
101. Ruze R, Liu T, Zou X, et al. Obesity and type 2 diabetes mellitus: connections in epidemiology, pathogenesis, and treatments. Front Endocrinol. 2023;14:1161521.
102. Moro C, Pasarica M, Elkind-Hirsch K, Redman LM. Aerobic exercise training improves atrial natriuretic peptide and catecholamine-mediated lipolysis in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2009;94:2579-86.
103. Lima-Silva AE, Adami F, Nakamura FY, de Oliveira FR, Gevaerd MS. Metabolismo de gordura durante o exercício físico: mecanismos de regulação. Rev Bras Cineantropometria Desempenho Hum. 2006;4:106-114. (in Portuguese)
104. Ljubicic V, Joseph AM, Saleem A, et al. Transcriptional and post-transcriptional regulation of mitochondrial biogenesis in skeletal muscle: effects of exercise and aging. Biochim Biophys Acta. 2010;1800:223-34.
105. Vecchiatto B, da Silva RC, Higa TS, et al. Oxidative phenotype induced by aerobic physical training prevents the obesity-linked insulin resistance without changes in gastrocnemius muscle ACE2-Angiotensin(1-7)-Mas axis. Diabetol Metab Syndr. 2021;13:74.
106. Ormsbee MJ, Choi MD, Medlin JK, et al. Regulation of fat metabolism during resistance exercise in sedentary lean and obese men. J Appl Physiol. 2009;106:1529-37.
107. Washburn RA, Kirk EP, Smith BK, et al. One set resistance training: effect on body composition in overweight young adults. J Sports Med Phys Fitness. 2012;52:273-9.
108. Polak J, Bajzova M, Stich V. Effect of exercise on lipolysis in adipose tissue. Future Lipidology. 2008;3:557-72.
109. Higa TS, Spinola AV, Fonseca-Alaniz MH, Evangelista FS. Remodeling of white adipose tissue metabolism by physical training prevents insulin resistance. Life Sci. 2014;103:41-8.
110. Américo ALV, Muller CR, Vecchiatto B, Martucci LF, Fonseca-Alaniz MH, Evangelista FS. Aerobic exercise training prevents obesity and insulin resistance independent of the renin angiotensin system modulation in the subcutaneous white adipose tissue. PLoS One. 2019;14:e0215896.
111. Anthony SR, Guarnieri AR, Gozdiff A, Helsley RN, Phillip Owens A, Tranter M. Mechanisms linking adipose tissue inflammation to cardiac hypertrophy and fibrosis. Clin Sci. 2019;133:2329-44.
112. Chondronikola M, Volpi E, Børsheim E, et al. Brown adipose tissue improves whole-body glucose homeostasis and insulin sensitivity in humans. Diabetes. 2014;63:4089-99.
113. Bartelt A, Bruns OT, Reimer R, et al. Brown adipose tissue activity controls triglyceride clearance. Nat Med. 2011;17:200-5.
114. Stanford KI, Middelbeek RJ, Townsend KL, et al. Brown adipose tissue regulates glucose homeostasis and insulin sensitivity. J Clin Invest. 2013;123:215-23.
115. Vidal P, Stanford KI. Exercise-induced adaptations to adipose tissue thermogenesis. Front Endocrinol. 2020;11:270.
116. Wang N, Liu Y, Ma Y, Wen D. High-intensity interval versus moderate-intensity continuous training: superior metabolic benefits in diet-induced obesity mice. Life Sci. 2017;191:122-31.
117. Motiani KK, Savolainen AM, Eskelinen JJ, et al. Two weeks of moderate-intensity continuous training, but not high-intensity interval training, increases insulin-stimulated intestinal glucose uptake. J Appl Physiol. 2017;122:1188-97.
118. Martinez-Tellez B, Sanchez-Delgado G, Acosta FM, et al. No evidence of brown adipose tissue activation after 24 weeks of supervised exercise training in young sedentary adults in the ACTIBATE randomized controlled trial. Nat Commun. 2022;13:5259.
119. Lehnig AC, Stanford KI. Exercise-induced adaptations to white and brown adipose tissue. J Exp Biol. 2018;221:jeb161570.
120. Wu J, Cohen P, Spiegelman BM. Adaptive thermogenesis in adipocytes: is beige the new brown? Genes Dev. 2013;27:234-50.
121. Otero-Díaz B, Rodríguez-Flores M, Sánchez-Muñoz V, et al. Exercise induces white adipose tissue browning across the weight spectrum in humans. Front Physiol. 2018;9:1781.
122. Kim HJ, Lee HJ, So B, Son JS, Yoon D, Song W. Effect of aerobic training and resistance training on circulating irisin level and their association with change of body composition in overweight/obese adults: a pilot study. Physiol Res. 2016;65:271-9.
123. Perakakis N, Triantafyllou GA, Fernández-Real JM, et al. Physiology and role of irisin in glucose homeostasis. Nat Rev Endocrinol. 2017;13:324-37.
124. Kim H, Wrann CD, Jedrychowski M, et al. Irisin mediates effects on bone and fat via αv integrin receptors. Cell. 2018;175:1756-68.e17.
125. Egan B, Zierath JR. Exercise metabolism and the molecular regulation of skeletal muscle adaptation. Cell Metab. 2013;17:162-84.
126. Drake JC, Wilson RJ, Yan Z. Molecular mechanisms for mitochondrial adaptation to exercise training in skeletal muscle. FASEB J. 2016;30:13-22.
127. Choe SS, Huh JY, Hwang IJ, Kim JI, Kim JB. Adipose tissue remodeling: its role in energy metabolism and metabolic disorders. Front Endocrinol. 2016;7:30.
128. Ring-Dimitriou S, Paulweber B, von Duvillard SP, et al. The effect of physical activity and physical fitness on plasma adiponectin in adults with predisposition to metabolic syndrome. Eur J Appl Physiol. 2006;98:472-81.
129. Lim S, Choi SH, Jeong IK, et al. Insulin-sensitizing effects of exercise on adiponectin and retinol-binding protein-4 concentrations in young and middle-aged women. J Clin Endocrinol Metab. 2008;93:2263-8.
130. Hulver MW, Zheng D, Tanner CJ, et al. Adiponectin is not altered with exercise training despite enhanced insulin action. Am J Physiol Endocrinol Metab. 2002;283:E861-5.
131. Jürimäe J, Purge P, Jürimäe T. Effect of prolonged training period on plasma adiponectin in elite male rowers. Horm Metab Res. 2007;39:519-23.
132. Recchia F, Leung CK, Yu AP, et al. Dose-response effects of exercise and caloric restriction on visceral adiposity in overweight and obese adults: a systematic review and meta-analysis of randomised controlled trials. Br J Sports Med. 2023;57:1035-41.
133. Lee S, Park Y, Dellsperger KC, Zhang C. Exercise training improves endothelial function via adiponectin-dependent and independent pathways in type 2 diabetic mice. Am J Physiol Heart Circ Physiol. 2011;301:H306-14.
134. Becic T, Studenik C, Hoffmann G. Exercise increases adiponectin and reduces leptin levels in prediabetic and diabetic individuals: systematic review and meta-analysis of randomized controlled trials. Med Sci. 2018;6:97.
135. Kanaley JA, Fenicchia LM, Miller CS, et al. Resting leptin responses to acute and chronic resistance training in type 2 diabetic men and women. Int J Obes Relat Metab Disord. 2001;25:1474-80.
136. Rosen ED, Spiegelman BM. Adipocytes as regulators of energy balance and glucose homeostasis. Nature. 2006;444:847-53.
137. Ozcelik O, Celik H, Ayar A, Serhatlioglu S, Kelestimur H. Investigation of the influence of training status on the relationship between the acute exercise and serum leptin levels in obese females. Neuro Endocrinol Lett. 2004;25:381-5.
138. Polak J, Klimcakova E, Moro C, et al. Effect of aerobic training on plasma levels and subcutaneous abdominal adipose tissue gene expression of adiponectin, leptin, interleukin 6, and tumor necrosis factor alpha in obese women. Metabolism. 2006;55:1375-81.
139. Covington JD, Tam CS, Pasarica M, Redman LM. Higher circulating leukocytes in women with PCOS is reversed by aerobic exercise. Biochimie. 2016;124:27-33.
140. Zafeiridis A, Smilios I, Considine RV, Tokmakidis SP. Serum leptin responses after acute resistance exercise protocols. J Appl Physiol. 2003;94:591-7.
141. Racil G, Zouhal H, Elmontassar W, et al. Plyometric exercise combined with high-intensity interval training improves metabolic abnormalities in young obese females more so than interval training alone. Appl Physiol Nutr Metab. 2016;41:103-9.
142. Thompson D, Karpe F, Lafontan M, Frayn K. Physical activity and exercise in the regulation of human adipose tissue physiology. Physiol Rev. 2012;92:157-91.
143. Silvestris E, de Pergola G, Rosania R, Loverro G. Obesity as disruptor of the female fertility. Reprod Biol Endocrinol. 2018;16:22.
144. Dantas WS, Neves WD, Gil S, et al. Exercise-induced anti-inflammatory effects in overweight/obese women with polycystic ovary syndrome. Cytokine. 2019;120:66-70.
